In a welcome move, Balchem saw its Relative Strength Rating rise from 68 to 74 on Tuesday.
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matched up against all other stocks.
Decades of market research shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Balchem can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Balchem is working on a consolidation with a 186.03 entry. See if the stock can break out in heavy volume.
Regarding top and bottom line numbers, the company has posted two quarters of rising earnings growth. Top line growth has also increased over the same time frame. The company is expected to report its next quarterly numbers on or around Apr. 25.
Balchem earns the No. 4 rank among its peers in the Chemicals-Specialty industry group. NewMarket is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
